CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total	Redeemable Noncontrolling Interests	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Total Shareholders' Equity Attributable to Bruker Corporation	Noncontrolling Interests in Consolidated Subsidiaries
Balance at beginning of period at Dec. 31, 2019	$ 917.1	$ 21.1	$ 1.7	$ (543.8)	$ 199.7	$ 1,274.7	$ (25.5)	$ 906.8	$ 10.3
Balance (in shares) at Dec. 31, 2019			154,155,798	19,346,577
Increase (Decrease) in Stockholders' Equity
Stock options exercised	4.9				4.9			4.9
Stock options exercised (in shares)			241,915
Restricted stock units vested	(1.6)				(1.6)			(1.6)
Restricted stock units vested (in shares)			301,320
Stock based compensation	13.3				13.3			13.3
Shares repurchased	(123.2)			$ (123.2)				(123.2)
Shares repurchased (in shares)			(2,711,952)	2,711,952
Distributions to noncontrolling interests	(1.2)								(1.2)
Acquired remaining 20% interest in Hain LifeScience GmbH	(1.3)	(20.6)				(1.3)		(1.3)
Cash dividends paid to common shareholders	(24.7)					(24.7)		(24.7)
Consolidated net (loss) income	161.4					157.8		157.8	3.6
Other comprehensive income (loss)	29.6	(0.5)					29.2	29.2	0.4
Balance at end of period at Dec. 31, 2020	974.3		$ 1.7	$ (667.0)	216.3	1,406.5	3.7	961.2	13.1
Balance (in shares) at Dec. 31, 2020			151,987,081	22,058,529
Increase (Decrease) in Stockholders' Equity
Stock options exercised	11.7				11.7			11.7
Stock options exercised (in shares)			580,656
Restricted stock units vested	(4.7)				(4.7)			(4.7)
Restricted stock units vested (in shares)			278,769
Stock based compensation	14.5				14.5			14.5
Shares repurchased	(153.3)			$ (153.3)				(153.3)
Shares repurchased (in shares)			(2,092,819)	2,092,819
Cash dividends paid to common shareholders	(24.1)					(24.1)		(24.1)
Formation of Acuity Spatial Genomics Inc.		0.3
Consolidated net (loss) income	280.7	(0.1)				277.1		277.1	3.6
Other comprehensive income (loss)	(14.5)						(11.9)	(11.9)	(2.6)
Balance at end of period at Dec. 31, 2021	1,084.6	0.2	$ 1.7	$ (820.3)	237.8	1,659.5	(8.2)	1,070.5	14.1
Balance (in shares) at Dec. 31, 2021			150,753,687	24,151,348
Increase (Decrease) in Stockholders' Equity
Stock options exercised	5.8				5.8			5.8
Stock options exercised (in shares)			251,006
Restricted stock units vested	(3.0)				(3.0)			(3.0)
Restricted stock units vested (in shares)			233,545
Stock based compensation	15.7				15.7			15.7
Shares repurchased	(264.7)			$ (264.7)				(264.7)
Shares repurchased (in shares)			(4,215,094)	4,215,094
Distributions to noncontrolling interests	(1.2)								(1.2)
Cash dividends paid to common shareholders	(29.8)					(29.8)		(29.8)
Consolidated net (loss) income	299.1	(0.6)				296.6		296.6	2.5
PreOmics Acquisition - other shareholders		6.8
Acquisition of minority interest	(3.1)					(0.3)	(0.2)	(0.5)	(2.6)
Other comprehensive income (loss)	22.3	(0.3)					23.2	23.2	(0.9)
Balance at end of period at Dec. 31, 2022	$ 1,125.7	$ 6.1	$ 1.7	$ (1,085.0)	$ 256.3	$ 1,926.0	$ 14.8	$ 1,113.8	$ 11.9
Balance (in shares) at Dec. 31, 2022			147,023,144	28,366,442